Dr. Lily Ackermann discussed inpatient diabetes care, focusing on real-world decisions and personalized treatment using ...

Novo Nordisk has developed a new version of the insulin analogue, called Fiasp, which added another DKK 1.6 billion to the fast-acting insulin pot last year and has patent protection to 2030.

Lilly will be hoping that the new titration regimen for Kisunla could tip the risk:benefit balance for its drug in favour of authorisations and help to drive uptake in the markets where it is ...